Suslov A P, Gering S, Kharkevich D D, Blandova Z K
Biull Eksp Biol Med. 1980 Apr;89(4):437-9.
Lymphocytes B10D2 anti-B10 (anti-KbIbDb) produce MIF when incubated with spleen cells of the recombinant KbIb-bearing R107 and Db-bearing R101 lines, possessing either public or private H-2 specificities of the immunizing complex. Cross reactivity revealed in the reaction with "unrelated" lines one week after immunization by allogeneic tumour disappeared during the second week; simultaneously the intensity of the reaction to KbIb and Db region products changes. The cross reaction of anti-Kb MIF producers obtained one week after immunization with cells of Kba and Kbd mutants disappeared two weeks after immunization: the migration inhibition which occurred one week after immunization turns to stimulation during the second week, while the degree of inhibition in the reaction with B10 cells remains unchanged.
B10D2抗B10(抗KbIbDb)淋巴细胞与携带重组KbIb的R107系和携带Db的R101系的脾细胞一起孵育时会产生巨噬细胞移动抑制因子(MIF),这两个系具有免疫复合物的公共或私有H-2特异性。同种异体肿瘤免疫一周后,与“无关”系反应中显示的交叉反应在第二周消失;同时,对KbIb和Db区域产物的反应强度发生变化。免疫一周后获得的抗Kb MIF产生细胞与Kba和Kbd突变体细胞的交叉反应在免疫两周后消失:免疫一周后出现的迁移抑制在第二周转变为刺激,而与B10细胞反应中的抑制程度保持不变。